 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...181182183184185186187188189190191...235236» |
- | Journal: Risk of Febrile Neutropenia Associated With Select Myelosuppressive Chemotherapy Regimens in a Large Community-Based Oncology Practice. (Pubmed Central) - May 1, 2018
From 2008 to 2013, 1,312 patients with breast cancer who received docetaxel and cyclophosphamide (TC; n=853) or docetaxel, carboplatin, and trastuzumab (TCH; n=459); 1,321 patients with colorectal cancer who received capecitabine and oxaliplatin (XELOX; n=401) or leucovorin, 5-fluorouracil, and oxaliplatin (FOLFOX6; n=920); 307 patients with non-Hodgkin's lymphoma who received bendamustine with or without rituximab; and 181 patients with multiple myeloma who received lenalidomide with or without dexamethasone were included...Calculation of chemotherapy course-level FN incidence without controlling for differential censoring for patients who discontinued regimens early, or possible FN misclassification, might have resulted in bias toward an underestimation of the true FN risk. These findings help define FN risk of the selected regimens in the real-world setting and inform prophylactic G-CSF use.
- | Imlygic (talimogene laherparepvec) / Amgen
Trial suspension, Surgery, Metastases: Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer (clinicaltrials.gov) - Apr 30, 2018
P1, N=21, Suspended, Sponsor: National Cancer Institute (NCI)
These findings help define FN risk of the selected regimens in the real-world setting and inform prophylactic G-CSF use. Recruiting --> Suspended
- |||||||||| Hanbeitai (bevacizumab biosimilar) / Fosun Pharma, Eurofarma
New P3 trial: A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC (clinicaltrials.gov) - Apr 30, 2018
P3, N=638, Recruiting, Sponsor: Shanghai Henlius Biotech
- || veliparib (ABT-888) / AbbVie
Trial primary completion date, Metastases: Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 27, 2018
P2, N=130, Completed, Sponsor: AbbVie
Recruiting --> Suspended Trial primary completion date: May 2017 --> Sep 2017
- | Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, Journal: Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer. (Pubmed Central) - Apr 26, 2018
It also captured data from private and community practices as well as academic centers. To our knowledge, this is the only data set that can give this degree of insight into oncologist decision making practices.
- | Viracept (nelfinavir) / ViiV Healthcare, Roche, OvaRex (oregovomab) / CanariaBio
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Apr 26, 2018
P2, N=12, Active, not recruiting, Sponsor: University of Nebraska
To our knowledge, this is the only data set that can give this degree of insight into oncologist decision making practices. Recruiting --> Active, not recruiting | N=66 --> 12 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Enrollment open, Trial completion date, Trial primary completion date: PANACHE01-PRODIGE48 Study: Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 26, 2018
P2, N=160, Recruiting, Sponsor: University Hospital, Rouen
Recruiting --> Active, not recruiting | N=66 --> 12 | Trial primary completion date: Dec 2018 --> Dec 2019 Not yet recruiting --> Recruiting | Trial completion date: Aug 2021 --> Dec 2021 | Trial primary completion date: Aug 2021 --> Dec 2021
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, LEAC-102 / Taiwan Bio
Trial completion date, Trial primary completion date, Combination therapy, Metastases: LEAC-102 for Advanced Colorectal Cancer (clinicaltrials.gov) - Apr 25, 2018
P1/2, N=30, Not yet recruiting, Sponsor: Taiwan Leader Biotech Corp.
Not yet recruiting --> Recruiting | Trial completion date: Aug 2021 --> Dec 2021 | Trial primary completion date: Aug 2021 --> Dec 2021 Trial completion date: Feb 2019 --> Feb 2022 | Trial primary completion date: Feb 2019 --> Feb 2022
- | Enlituo (cetuximab biosimilar) / Mabpharm Limited, Sorrento
Enrollment open, Metastases: CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 25, 2018
P3, N=512, Recruiting, Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd
Trial completion date: Feb 2019 --> Feb 2022 | Trial primary completion date: Feb 2019 --> Feb 2022 Not yet recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., sorafenib / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Sorafenib + mFOLFOX for Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 24, 2018
P2, N=40, Active, not recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: May 2017 --> Dec 2018 | Trial primary completion date: May 2017 --> Jul 2018
- | Sotyktu (deucravacitinib) / BMS
Trial completion, Enrollment change: A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients (clinicaltrials.gov) - Apr 23, 2018
P1, N=30, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | Trial completion date: May 2017 --> Dec 2018 | Trial primary completion date: May 2017 --> Jul 2018 Recruiting --> Completed | N=12 --> 30
- ||||| Vyloy (zolbetuximab-clzb) / Astellas
Biomarker, New P2 trial, Monotherapy, PD(L)-1 Biomarker: ILUSTRO: A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer (clinicaltrials.gov) - Apr 22, 2018
P2, N=102, Not yet recruiting, Sponsor: Astellas Pharma Global Development, Inc.
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Journal: Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017. (Pubmed Central) - Apr 22, 2018
For patients who are robust enough to receive second-line therapy (and beyond), the selection of treatment depends in part on their prior treatment exposure; newer drugs such as nanoliposomal irinotecan (nal-IRI) (in combination with infusional 5-fluorouracil and leucovorin) are now approved by the United States Food and Drug Administration (FDA) specifically for use following disease progression on first-line gemcitabine-based therapy. Despite these welcome advances in standard of care treatment, patients should still be encouraged to participate in clinical trials whenever possible.
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. (Pubmed Central) - Apr 20, 2018
P2
Despite these welcome advances in standard of care treatment, patients should still be encouraged to participate in clinical trials whenever possible. This study will help define standard preoperative treatment regimens for borderline resectable pancreatic cancer and position the superior arm for further evaluation in future phase III trials.
- |||||||||| Vyloy (zolbetuximab-clzb) / Astellas
New P3 trial, Metastases: Spotlight: A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (clinicaltrials.gov) - Apr 19, 2018
P3, N=550, Not yet recruiting, Sponsor: Astellas Pharma Global Development, Inc.
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
New P3 trial, Metastases: Avenger 500: Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Apr 19, 2018
P3, N=500, Not yet recruiting, Sponsor: Rafael Pharmaceuticals Inc.
- | Trial primary completion date: Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 18, 2018
P2, N=66, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
This study will help define standard preoperative treatment regimens for borderline resectable pancreatic cancer and position the superior arm for further evaluation in future phase III trials. Trial primary completion date: Feb 2018 --> Nov 2017
- Folotyn (pralatrexate) / Aurobindo
Trial completion date, Trial primary completion date, Combination therapy: Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies (clinicaltrials.gov) - Apr 18, 2018
P2, N=37, Recruiting, Sponsor: Spectrum Pharmaceuticals, Inc
Trial primary completion date: Feb 2018 --> Nov 2017 Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- Stivarga (regorafenib) / Bayer
Trial completion date, Trial primary completion date, Metastases: FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer (clinicaltrials.gov) - Apr 18, 2018
P2, N=36, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Jul 2019
- | floxuridine / Generic mfg.
New P3 trial: HARVEST: Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM (clinicaltrials.gov) - Apr 17, 2018
P3, N=288, Recruiting, Sponsor: Sun Yat-sen University
- | Phase classification, Metastases: Modified-FOLFIRINOX Regimen Based Neoadjuvant Therapy in Chinese Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Apr 17, 2018
P, N=41, Completed, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Jul 2019 Phase classification: P=N/A --> P
- | Trial completion date, Trial primary completion date: Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Apr 17, 2018
P=N/A, N=42, Active, not recruiting, Sponsor: Philip Philip
Phase classification: P=N/A --> P Trial completion date: Nov 2017 --> Jun 2018 | Trial primary completion date: Nov 2017 --> Jun 2018
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Surgery, Metastases: Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Apr 17, 2018
P1b/2, N=68, Recruiting, Sponsor: Mayo Clinic
Trial completion date: Nov 2017 --> Jun 2018 | Trial primary completion date: Nov 2017 --> Jun 2018 Trial completion date: Apr 2018 --> Apr 2021 | Trial primary completion date: Apr 2018 --> Apr 2021
- | palupiprant (AN0025) / Eisai, Adlai Nortye
Trial primary completion date, Combination therapy: PRAER 1: Preoperative Radiotherapy and E7046 in Rectum Cancer (clinicaltrials.gov) - Apr 17, 2018
P1b, N=68, Recruiting, Sponsor: Adlai Nortye Biopharma Co., Ltd.
Trial completion date: Apr 2018 --> Apr 2021 | Trial primary completion date: Apr 2018 --> Apr 2021 Trial primary completion date: Apr 2018 --> Sep 2018
- Avonex (recombinant IFN-?-1a) / Biogen
Enrollment change: Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX (clinicaltrials.gov) - Apr 12, 2018
P4, N=0, Withdrawn, Sponsor: MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Trial primary completion date: Apr 2018 --> Sep 2018 N=20 --> 0
- | Trial completion date, Metastases: Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 10, 2018
P2, N=44, Active, not recruiting, Sponsor: University of Florida
N=20 --> 0 Trial completion date: Apr 2018 --> Jul 2018
- | Erbitux (cetuximab) / Eli Lilly
New P2 trial: TRICE: Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM (clinicaltrials.gov) - Apr 9, 2018
P2, N=140, Recruiting, Sponsor: Sun Yat-sen University
- | 5-fluorouracil / Generic mfg.
Trial completion date, Trial primary completion date, Surgery: Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer (clinicaltrials.gov) - Apr 9, 2018
P2, N=248, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Apr 2018 --> Jul 2018 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Trial completion, Metastases: Molecularly Tailored Therapy for Pancreas Cancer (clinicaltrials.gov) - Apr 9, 2018
P2, N=19, Completed, Sponsor: Georgetown University
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Completed
- | Biomarker, Trial suspension, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Apr 9, 2018
P2, N=1400, Suspended, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Suspended
- | Clinical, Journal: Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. (Pubmed Central) - Apr 6, 2018
We performed a prospective, preplanned, pooled analysis of six randomized, phase 3 trials that were conducted concurrently to evaluate the noninferiority of adjuvant therapy with either FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin) administered for 3 months, as compared with 6 months...However, in patients treated with CAPOX, 3 months of therapy was as effective as 6 months, particularly in the lower-risk subgroup. (Funded by the National Cancer Institute and others.).
- || Vectibix (panitumumab) / Amgen
Phase classification, HEOR: SILQ: ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line (clinicaltrials.gov) - Apr 6, 2018
P, N=300, Recruiting, Sponsor: Amgen
(Funded by the National Cancer Institute and others.). Phase classification: P=N/A --> P
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Phase classification: Post Marketing Surveillance Study for ONIVYDE (clinicaltrials.gov) - Apr 6, 2018
P, N=78, Recruiting, Sponsor: Shire
Phase classification: P=N/A --> P Phase classification: P=N/A --> P
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer (clinicaltrials.gov) - Apr 6, 2018
P2, N=56, Active, not recruiting, Sponsor: John Hays
Phase classification: P=N/A --> P Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- | sorafenib / Generic mfg.
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC (clinicaltrials.gov) - Apr 5, 2018
P3, N=247, Active, not recruiting, Sponsor: Sun Yat-sen University
Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting | N=162 --> 247 | Trial completion date: Dec 2018 --> Aug 2018 | Trial primary completion date: Dec 2017 --> Jul 2017
- || Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date: Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Apr 4, 2018
P2, N=78, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting | N=162 --> 247 | Trial completion date: Dec 2018 --> Aug 2018 | Trial primary completion date: Dec 2017 --> Jul 2017 Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Mar 2018 --> Mar 2019
- |||| GC-1118A / GC Biopharma
Enrollment open, Combination therapy, Metastases: A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy (clinicaltrials.gov) - Apr 4, 2018
P1b/2a, N=53, Recruiting, Sponsor: Green Cross Corporation
Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Mar 2018 --> Mar 2019 Not yet recruiting --> Recruiting
- | New P2 trial: Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer (clinicaltrials.gov) - Apr 3, 2018
P2, N=30, Not yet recruiting, Sponsor: China Medical University, China
- ||||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
New P2 trial, Combination therapy: Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 3, 2018
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
- || napabucasin (BBI608) / Sumitomo Pharma
Trial primary completion date, Combination therapy, Metastases: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer (clinicaltrials.gov) - Apr 3, 2018
P1, N=250, Active, not recruiting, Sponsor: Boston Biomedical, Inc
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2018 --> Dec 2018
- | Enrollment open, Combination therapy, IO biomarker: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) - Apr 3, 2018
P2, N=26, Recruiting, Sponsor: University of Miami
Trial primary completion date: Jun 2018 --> Dec 2018 Active, not recruiting --> Recruiting
- || eftozanermin alfa (ABBV-621) / AbbVie, Apogenix
Enrollment change: A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies (clinicaltrials.gov) - Apr 3, 2018
P1, N=92, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Recruiting N=150 --> 92
- || dilpacimab (ABT-165) / AbbVie
Trial primary completion date, Metastases: A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab (clinicaltrials.gov) - Apr 2, 2018
P2, N=100, Recruiting, Sponsor: AbbVie
N=150 --> 92 Trial primary completion date: Aug 2019 --> Feb 2020
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
New P2 trial, Metastases: Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 2, 2018
P2, N=42, Recruiting, Sponsor: Fudan University
- | Trial primary completion date: Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Mar 30, 2018
P2, N=50, Enrolling by invitation, Sponsor: Nagoya University
Trial primary completion date: Aug 2019 --> Feb 2020 Trial primary completion date: Jun 2017 --> Jun 2020
- |||||| Vectibix (panitumumab) / Amgen
Enrollment open: 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab (clinicaltrials.gov) - Mar 30, 2018
P3, N=450, Recruiting, Sponsor: University of Southern California
Trial primary completion date: Jun 2017 --> Jun 2020 Not yet recruiting --> Recruiting
- | New P2 trial, Metastases: Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer (clinicaltrials.gov) - Mar 30, 2018
P2, N=30, Not yet recruiting, Sponsor: China Medical University, China
- | New P2 trial, Metastases: Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Mar 30, 2018
P2, N=30, Not yet recruiting, Sponsor: China Medical University, China
- | New P1 trial: Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Mar 30, 2018
P1, N=20, Not yet recruiting, Sponsor: University of Louisville
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical, Journal: Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. (Pubmed Central) - Mar 30, 2018
PST using mFOLFIRINOX in resectable PDAC is feasible and tolerable. R0 resection rate is high and survival promising, requiring longer follow-up and larger studies for definitive assessment.